MedPath

evel of IgG Antibodies against Covid19 in people of Ahmedabad as on February 2021

Not Applicable
Registration Number
CTRI/2021/02/031165
Lead Sponsor
Ahmedabad Municipal Corporation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Those who give written informed consent

Exclusion Criteria

any bleeding disorder, contraindication to venipuncture & hospitalized patients

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Seroprevalence of IgG Antibodies against SARS-CoV-2 in general population of AhmedabadTimepoint: 1 (since this is a cross sectional study (A serosurveillance using Covid-Kavach - IgG antibody for SARS-CoV2) there is only 1 time-point)
Secondary Outcome Measures
NameTimeMethod
Factors Affecting IgG antibody based Immunity against SARS-CoV-2 infectionTimepoint: 1 (since this is a cross sectional study (A serosurveillance using Covid-Kavach - IgG antibody for SARS-CoV2) there is only 1 time-point)
© Copyright 2025. All Rights Reserved by MedPath